Thelansis

 IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure known as secretory IgA. Plasma cells mainly produce secretory IgA in a polymeric form, consisting of multiple monomers linked by the J-chain, a 17-kDa polypeptide. In IgAN, the kidneys sustain the primary damage. The disease follows a gradual yet relentless clinical course, leading to end-stage renal disease (ESRD) in approximately 30-40% of patients within 20-30 years. IgAN can manifest in sporadic cases (90-95%) or familial cases (5-10%). Individual...

  IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis in the world. The primary defect of the disease is systemic aberrant glycosylation of O­linked glycans (glycoproteins) in the hinge region of IgA1, resulting in elevated serum levels of galactose-deficient IgA1 (GdIgA1), which is recognised by glycan-specific IgA and IgG autoantibodies. IgA is an antibody that plays an important part in mucosal immunity. Prevalence is modest in the United States (10–20% of primary glomerulonephritis), higher in some European countries (20–30%), and highest in developed countries in Asia (40–50%). Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potenti...

Immunoglobulin A Nephropathy, called IgAN for short, or Berger’s disease, that occurs when IgA deposits build up in the kidneys and that damages the glomeruli and can cause kidney disease. Etiology- IgA nephropathy is an autoimmune kidney disease. IgA nephropathy have an increased blood level of IgA that contains less of a special sugar, galactose, than normal. This galactose-deficient IgA is considered “foreign” by other antibodies circulating in the blood. As a result, these other antibodies attach to the galactose-deficient IgA and form a clump. This clump is also called an immune complex. Epidemiology- About 1 in every 4 adults with IgA nephropathy eventually gets kidney failure/ESRD. One in every 10 to 20 children will get kidney failure/ESRD because of IgA nephropathy.   The competitive landscape of IgA Nephropathy includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked ...